Tumors hijack healthy lung cells to build their own lipid supply line - and cutting it slows metastasis

Cancer's greatest trick may not be how it grows. It may be how it shops.

Two studies published simultaneously - one in Nature Cell Biology, the other in Cancer Discovery - reveal that breast cancer cells metastasizing to the lungs do not simply arrive and multiply. They recruit the lung's own cells, reprogram them into lipid factories, and then use those lipids not as fuel, as long assumed, but as molecular signals that rewrite the cancer cells' own growth program.

The work, from Sarah-Maria Fendt's team at the VIB-KU Leuven Center for Cancer Biology in collaboration with Mariia Yuneva at the Francis Crick Institute, points to a therapeutic strategy that targets the lung's supply line rather than the tumor itself.

The lung cell that becomes an accomplice

The lung harbors a specialized cell type called alveolar type II (AT2) cells. Previous research from Fendt's group had shown that AT2 cells help prepare distant organs for cancer's arrival - a process sometimes called pre-metastatic niche formation. But what these cells do after metastases are already established was poorly understood.

The Cancer Discovery study, led by first author Dr. Xiao-Zheng Liu, found that breast cancer metastases actively recruit AT2 cells and reprogram them to ramp up lipid production. "We discovered that cancer cells recruit AT2 cells and reprogram them to produce more lipids for them," Liu said.

When the researchers reduced the lipid supply from AT2 cells, metastatic growth slowed. The tumor depended on its host tissue for raw materials it could not - or did not - produce on its own.

Lipids as signals, not just energy

The companion study in Nature Cell Biology, led by first author Dr. Ming Liu, addressed a deeper question: what do cancer cells actually do with these lipids?

Lipids are high-energy molecules. The conventional assumption was that cancer cells metabolize them for fuel. The Fendt lab found something different. Cancer cells use a specific lipid component called palmitate to modify proteins through a process called palmitoylation - attaching fatty acid chains to proteins to alter their function. These lipid modifications changed the molecular profile of cancer cells in ways that promoted growth specifically in the lung environment.

"The key insight was that these lipids are not just used as an energy source," Fendt said. "Instead, they initiate the molecular pathway that enables cancer cells to modify themselves and grow. When we interrupt this process, we can block metastatic growth."

Strength in replication

The two studies were conducted in different laboratories with different models and different techniques but reached converging conclusions. That replication across institutions - VIB-KU Leuven in Belgium and the Francis Crick Institute in London - gives the findings a robustness that single-lab discoveries often lack.

"We were able to obtain the same results in different laboratories, with different models and with different techniques," Yuneva said. "Bringing our complementary expertise together made the study very robust."

Refining who gets lipid-targeting drugs

Several clinical trials are already testing drugs that inhibit lipid production in cancer. The challenge has been identifying which patients are most likely to respond. These studies suggest a potential answer: patients whose lung metastases recruit large numbers of AT2 cells may benefit most from lipid synthesis inhibitors.

"Our findings suggest that these inhibitors may best work in patients whose metastasis recruit large amounts of AT2 cells," Fendt said. If validated, this could help refine patient selection for ongoing trials - a practical step toward personalized treatment.

From breast cancer to lung cancer?

The studies focused on breast cancer metastases in the lung. But the researchers note that AT2 cells could play a similar lipid-supply role for other tumors that grow in lung tissue, including primary lung cancers. A direct link between AT2-derived lipids and primary lung cancer growth has not yet been established, but the observed interactions point in that direction.

The work also carries a broader conceptual lesson. Cancer has traditionally been studied as a disease of the tumor cell - its mutations, its growth signals, its evasion of immune detection. These studies shift the frame. The critical vulnerability may not be in the cancer cell at all but in the normal tissue it corrupts. Cut the supply line, and the invader may starve.